Provided by Tiger Fintech (Singapore) Pte. Ltd.

Dyne Therapeutics, Inc.

9.33
+1.1614.20%
Post-market: 9.690.3600+3.86%18:01 EDT
Volume:4.51M
Turnover:41.60M
Market Cap:1.06B
PE:-2.77
High:9.79
Open:8.17
Low:8.01
Close:8.17
Loading ...

Dyne announces new long-term data from Phase 1/2 DELIVER trial of DYNE-251

TIPRANKS
·
17 Mar

Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

GlobeNewswire
·
11 Mar

Dyne Therapeutics Initiated at Sector Outperform by Scotiabank

Dow Jones
·
08 Mar

Stock Track | Dyne Therapeutics Plummets 5.22% as Q4 Losses Exceed Expectations

Stock Track
·
03 Mar

Dyne Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
03 Mar

Dyne Therapeutics (DYN) Gets a Buy from Stifel Nicolaus

TIPRANKS
·
02 Mar

Morgan Stanley Keeps Their Buy Rating on Dyne Therapeutics (DYN)

TIPRANKS
·
28 Feb

Dyne Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
28 Feb

Analysts Offer Insights on Healthcare Companies: Lemaitre Vascular (LMAT), Dyne Therapeutics (DYN) and Kymera Therapeutics (KYMR)

TIPRANKS
·
28 Feb

Dyne Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
28 Feb

RBC Cuts Price Target on Dyne Therapeutics to $41 From $45, Keeps Outperform, Speculative Risk

MT Newswires Live
·
28 Feb

Buy Rating for Dyne Therapeutics: Promising Accelerated Approval Potential for DYNE-101 and DYNE-251

TIPRANKS
·
28 Feb

Dyne Therapeutics price target lowered to $46 from $55 at H.C. Wainwright

TIPRANKS
·
28 Feb

Dyne Therapeutics Advances Clinical Programs Amid Financial Losses

TIPRANKS
·
28 Feb

Dyne Therapeutics Q4 Net Loss Narrows; Shares Rise

MT Newswires Live
·
27 Feb

Earnings Flash (DYN) Dyne Therapeutics Reports Q4 Loss $0.88, vs. FactSet Est of $0.94 Loss

MT Newswires Live
·
27 Feb

Corrected-Dyne Therapeutics Q4 EPS USD -0.88 VS. Ibes Estimate USD -0.96 (Corrects Amount)

THOMSON REUTERS
·
27 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
27 Feb

Jefferies Group's Strategic Moves: Amazon.com Inc. Takes Center Stage with 2.28% Portfolio Impact

GuruFocus.com
·
15 Feb

After Plunging -10.43% in 4 Weeks, Here's Why the Trend Might Reverse for Dyne Therapeutics (DYN)

Zacks
·
13 Feb